Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 894.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,381 shares of the biopharmaceutical company's stock after buying an additional 4,840 shares during the quarter. Tower Research Capital LLC TRC's holdings in Alnylam Pharmaceuticals were worth $1,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ALNY. Capital World Investors grew its position in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after buying an additional 92,101 shares during the period. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after acquiring an additional 98,303 shares in the last quarter. Capital Research Global Investors raised its holdings in Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $1,045,822,000. Finally, Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $577,941,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALNY. Stifel Nicolaus upped their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Royal Bank of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. Finally, Chardan Capital restated a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Insider Buying and Selling

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 59,984 shares of company stock valued at $16,864,347 over the last quarter. 1.20% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Up 3.7 %

Shares of NASDAQ ALNY traded up $8.95 during mid-day trading on Friday, reaching $251.56. 835,531 shares of the company were exchanged, compared to its average volume of 879,273. Alnylam Pharmaceuticals, Inc. has a 1 year low of $143.50 and a 1 year high of $304.39. The stock has a market cap of $32.72 billion, a price-to-earnings ratio of -115.93 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a 50-day moving average of $247.37 and a 200 day moving average of $256.00.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.